One-year chronic oral toxicity with combined reproduction toxicity study of a novel probiotic, Bacillus coagulans, as a food ingredient

Food and Chemical Toxicology

Volumn 49, Issue 5, 2011, Pages 1174-1182

  Endres, J R ^a   Qureshi, I ^a   Farber, T ^b   Hauswirth, J ^c   Hirka, G ^d   Pasics, I ^d   Schauss, A G ^a  

^a AIBMR Life Sciences Inc   (United States)

^b Toxicology Advisory Services   (United States)

^c Van Gemert and Hauswirth LLC   (United States)

^d Toxi Coop Toxicological Research Center Zrt   (Hungary)

Author keywords

Bacillus coagulans; Functional foods; GanedenBC30 ; Gastrointestinal flora; GRAS; Probiotic

Indexed keywords

GANEDEN; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BEHAVIOR DISORDER; CHRONIC DRUG ADMINISTRATION; CHRONIC TOXICITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ESTRUS CYCLE; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; MALE; MATING; NONHUMAN; ORGAN WEIGHT; PREGNANCY OUTCOME; RAT; REPRODUCTIVE TOXICITY; TOXICITY TESTING;

ADMINISTRATION, ORAL; ANIMALS; BACILLUS; CONSUMER PRODUCT SAFETY; DIET; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD ANALYSIS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PROBIOTICS; RATS; RATS, WISTAR; REPRODUCTION; TOXICITY TESTS, CHRONIC;

BACILLUS COAGULANS; RATTUS NORVEGICUS;

EID: 79953036443     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2011.02.012     Document Type: Article

References (27)

1. Adami A., Cavazzoni V. Occurrence of selected bacterial groups in the faeces of piglets fed with Bacillus coagulans as probiotic. J. Basic Microbiol. 1999, 39:3-9.
2. Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad. Med. 2009, 121:114-118.
3. Bezkorovainy A. Probiotics: Determinants of survival and growth in the gut. Am. J. Clin. Nutr. 2001, 73:399S-405S.
4. De Clerck E., Rodriguez-Diaz M., Forsyth G., et al. Polyphasic characterization of Bacillus coagulans strains, illustrating heterogeneity within this species, and amended description of the species. Syst. Appl. Microbiol. 2004, 27:50-60.
5. De Vecchi E., Drago L. Lactobacillus Sporogenes or Bacillus Coagulans: misidentification or mislabelling?. Int. J. of Probiot. Prebiot. 2006, 1:3-10.
6. Dolin B.J. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant Irritable Bowel Syndrome. Meth. Find Exp. Clin. Pharmacol. 2009, 31:655-659.
7. Donskey C.J., Hoyen C.K., Das S.M., et al. Effect of oral Bacillus coagulans administration on the density of vancomycin-resistant enterococci in the stool of colonized mice. Lett. Appl. Microbiol. 2001, 33:84-88.
8. Endres J.R., Clewell A., Jade K.A., et al. Safety assessment of a proprietary preparation of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem. Toxicol. 2009, 47:1231-1238.
9. Gandhi A.B. Probiotic lactic acid bacteria. Eastern Pharmacist 1994, 37:43.
10. Graff S., Chaumeil J.C., Boy P., et al. Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition. Biol. Pharm. Bull. 2008, 31:266-272.
11. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad. Med. 2009, 121:119-124.
12. Hyronimus B., LeMarrec C., Sassi A.H., et al. Acid and bile tolerance of spore-forming lactic acid bacteria. Int. J. Food Microbiol. 2000, 61:193-197.
13. Kalman D.S., Schwartz H.I., Alvarez P., et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol. 2009, 85(9).
14. Katsutoshi A., Meguro S., Hase T., et al. Effect spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microb. Ecol. Health Dis. 2003, 14:4-13.
15. Kimmel M, Keller D, Farmer S, et al. A controlled clinical trial to evaluate the effect of GanedenBC30 on immunological markers. Meth. Find Exp. Clin. Pharmacol. 2010;32 epub ahead of print.
16. Lee Y.K. Handbook of Probiotics 1999, John Wiley & Sons, New York.
17. Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A.L. Helicobacter pylori and probiotics. J. Nutr. 2007, 137:812S-818S.
18. Ljungh A., Wadstrom T. Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 2006, 7:73-89.
19. Mandel D.R., Eichas K., Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern. Med. 2010, 10:1.
20. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008, 14:2650-2661.
21. Ouwehand A.C. Antiallergic effects of probiotics. J. Nutr. 2007, 137:794S-797S.
22. Patel M.A., Ou M.S., Harbrucker R., et al. Isolation and characterization of acid-tolerant, thermophilic bacteria for effective fermentation of biomass-derived sugars to lactic acid. Appl. Environ. Microbiol. 2006, 72:3228-3235.
23. Quigley E.M. Probiotics in irritable bowel syndrome: an immunomodulatory strategy?. J. Am. Coll. Nutr. 2007, 26:684S-690S.
24. Rastall R.A., Gibson G.R., Gill H.S., et al. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol. Ecol. 2005, 52:145-152.
25. Sarles W.B., Hammer B.W. Observations on Bacillus coagulans. J. Bacteriol. 1932, 23:301-314.
26. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol. Ther. 2008, 28:385-396.
27. Tappenden K.A., Deutsch A.S. The physiological relevance of the intestinal microbiota-contributions to human health. J. Am. Coll. Nutr. 2007, 26:679S-683S.